Deborah Cromer

New work from @KirbyInstitute shows viral clearance predicts clinical protection after COVID-19 treatment. Super important finding to speed up drug development to protect vulnerable populations. Great working with @ProfStephenKent @markpoliz @Tari_Turner thelancet.com/journals/lanmi…

Our latest manuscript aggregates all available data to show that updated COVID vaccines increase antibodies to a future variant by 40% compared to last season's vaccine. Another great @KirbyInstitute collaboration between @IAP_Sydney and @viralvaxlab medrxiv.org/content/10.110…

Strong link between early viral load reduction by anti-COVID treatments and clinical efficacy. Helps rapidly progress better treatments. Bravo, great work by Khoury, Davenport and team. @IAP_Sydney @TheDohertyInst @KirbyInstitute @viralvaxlab medrxiv.org/content/10.110…

Great news - new evidence shows that the effectiveness of COVID-19 treatments can be determined based on how fast treated subjects can clear the virus. medrxiv.org/content/10.110… More great work from @IAP_Sydney at @KirbyInstitute

Get boosted! Our new research in Nature Medicine shows both normal and bivalent boosters increase antibody levels, though variant boosters give on average 60% more antibodies. #COVID19Abs nature.com/articles/s4159… @IAP_Sydney @KirbyInstitute @ProfStephenKent

Neutralizing #antibody titers elicited by either ancestral or bivalent #COVID19 #vaccine boosters are predicted to increase protection against severe disease due to #SARSCoV2 variants. @DebCro @IAP_Sydney @KirbyInstitute nature.com/articles/s4159…

Another win for neutralising antibodies! Who would have thought they are also correlated with protection against Severe COVID-19?? (Well maybe @IAP_Sydney would!) #COVID19Abs nature.com/articles/s4146… Great working with @m_steain @sarah_sasson @ProfStephenKent @KirbyInstitute

Do you like your covid-19 vaccines to give you a good dose of neutralising antibodies? You should because we've shown they correlate not only with protection from symptomatic but also severe disease! Another great collab with ⁦@DebCro⁩ nature.com/articles/s4146…

Some data (to complement the range of opinions) on variant boosters in our latest preprint medrxiv.org/content/10.110…

Our latest meta-analysis comparing ancestral + variant based boosters. Shows the gain from variant boosters is very dependent on the existing protection in the population. medrxiv.org/content/10.110… @IAP_Sydney @KirbyInstitute @ProfStephenKent @kanta_subbarao @TheDohertyInst

Follow up on this seminar - the paper I was discussing on correlates of severe COVID-19 is now up as a preprint here medrxiv.org/content/10.110…

What role do T cells play in vaccine-induced immunity to SARS-CoV-2? Discussed here: go.nature.com/3y9zhIV @sarah_sasson @DebCro @TricckyLab @profstephenkent @viralvaxlab @EJohnWherry #COVID-19 #vaccines #SARSCoV2

Our latest preprint shows that neutralising antibodies predict protection from severe COVID-19. Great collaborating with @ProfStephenKent @m_steain on this important work from the @KirbyInstitute medrxiv.org/content/10.110…

New preprint from our group combining work from multiple studies and showing a threshold for neutralising antibodies protecting from SARS-CoV-2. Great collaborating as always with @ProfStephenKent @m_steain @TricckyLab medrxiv.org/content/10.110…

Commentary in @Nature on our analysis of dosing and timing of antibody therapies for COVID-19 Pre-print at medRxiv doi.org/10.1101/2022.0…

Check out Dr Deborah Cromer's interview with @normanswan on today's @RadioNational Health Report discussing our analysis of antibody treatments for COVID-19 abc.net.au/radionational/… @KirbyInstitute @markpoliz @AndelLestcourt @NSkoetz @Monash_SPHPM

@EricTopol @ASPRgov @HHS_ASPR @EricTopol Have you seen our preprint showing that passive abs are most effective when given earlier, and could have been given at much lower doses to achieve 90% of the efficacy? (available online today) doi.org/10.1101/2022.0… twitter.com/DebCro/status/…

A very helpful @ASPRgov resource to locate the limited supply of Paxlovid and monoclonal antibodies effective vs the Omicron lineages …rapeutics-locator-dhhs.hub.arcgis.com @HHS_ASPR

New work from our group showing passive antibodies work best when given early. Very effective as prophylaxis / in early stages - once in hospital they have little to no effect. Determinants of passive antibody effectiveness in SARS-CoV-2 infection doi.org/10.1101/2022.0…

NSW COVID-19 update – Sunday 23 January 2022 In the 24-hour reporting period to 8pm last night: - 95.3% of people aged 16+ have had one dose of a COVID-19 vaccine - 93.9% of people aged 16+ have had two doses of a COVID-19 vaccine

@NSWHealth 3

NSW COVID-19 update – Sunday 26 December 2021 In the 24-hour reporting period to 8pm last night: - 95% of people aged 16+ have had one dose of a COVID-19 vaccine - 93.5% of people aged 16+ have had two doses of a COVID-19 vaccine